Parallel Advisors’s Celldex Therapeutics CLDX Stock Holding History

Parallel Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.91K	Sell	132 -32	-20%	-$1.03K	﹤0.01%	3215
2026 Q1	$5.2K	Buy	164 +90	+122%	+$2.45K	﹤0.01%	3016
2025 Q4	$2.01K	Hold	74	–	–	﹤0.01%	3130
2025 Q3	$1.91K	Hold	74	–	–	﹤0.01%	3058
2025 Q2	$1.51K	Sell	74 -859	-92%	-$16.7K	﹤0.01%	3112
2025 Q1	$16.9K	Buy	933 +854	+1,081%	+$19.1K	﹤0.01%	2219
2024 Q4	$2K	Buy	79 +57	+259%	+$1.55K	﹤0.01%	2970
2024 Q3	$748	Hold	22	–	–	﹤0.01%	3096
2024 Q2	$814	Hold	22	–	–	﹤0.01%	3008
2024 Q1	$923	Hold	22	–	–	﹤0.01%	2951
2023 Q4	$873	Hold	22	–	–	﹤0.01%	2967
2023 Q3	$605	Hold	22	–	–	﹤0.01%	3071
2023 Q2	$746	Sell	22 -2	-8%	-$67	﹤0.01%	3004
2023 Q1	$864	Hold	24	–	–	﹤0.01%	2992
2022 Q4	$1.07K	Sell	24 -2	-8%	-$71	﹤0.01%	2881
2022 Q3	$1K	Buy	26 +4	+18%	+$123	﹤0.01%	2866
2022 Q2	$1K	Buy	+22	New	+$639	﹤0.01%	2722

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Parallel Advisors's CLDX Position: Q2 2026 in Review

Parallel Advisors reduced its Celldex Therapeutics (CLDX) stake by 20% in Q2 2026, selling an estimated $1.03K and leaving 132 shares worth $4.91K. The position accounts for ﹤0.01% of the portfolio, ranked #3215.

Parallel Advisors first reported a position in CLDX in Q2 2022 and has held it in 17 quarters since. The position peaked at $16.9K in Q1 2025. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

Parallel Advisors held 132 shares of Celldex Therapeutics worth $4.91K as of Q2 2026.
Parallel Advisors sold 32 Celldex Therapeutics shares in Q2 2026, an estimated $1.03K.
Celldex Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3215 holding.
Parallel Advisors first reported a position in Celldex Therapeutics in Q2 2022 and has held it in 17 quarters since.
Parallel Advisors's Celldex Therapeutics position peaked at $16.9K in Q1 2025.
253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.